MAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, from April 13 to 18, 2024. Representatives from Upsher-Smith will be on hand at Booth #818 to showcase its expanding portfolio of medications backed by the Promise of Support™ Program, including the VIGADRONE® (vigabatrin) product family and TORPENZ™ (everolimus) Tablets slated for availability in mid-2024.
Bora Pharmaceuticals Completes the Acquisition of Upsher-Smith
MAPLE GROVE, Minn., March 29, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according to IQVIA. The Therapeutic Equivalence (TE) code for the product is AB, and the original Reference Listed Drug (RLD) was the brand Tapazole®*.
MAPLE GROVE, Minn., Feb. 6, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) proudly announce the recipients of the 2023 NASPA Excellence in Innovation Award. This annual award, overseen by NASPA and sponsored by Upsher-Smith, acknowledges innovative pharmacists from across the nation for their outstanding contributions to the field of pharmacy.
Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion
MAPLE GROVE, Minn. , Nov. 6, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Pitavastatin Tablets in 1 mg, 2 mg, and 4 mg strengths. The Pitavastatin Tablet market had U.S. sales of approximately $302 million for the 12 months ending August 2023 according to IQVIA. Pitavastatin Tablets are an AB-rated, generic equivalent to the brand product, LIVALO® (pitavastatin) tablets.*
MAPLE GROVE, Minn., Aug. 21, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Mesalamine Extended-Release Capsules, USP 375 mg. The mesalamine capsule market had U.S. sales of approximately $105 million for the 12 months ending June 2023 according to IQVIA. Upsher-Smith's Mesalamine Extended-Release Capsules are AB-rated to APRISO® (mesalamine) extended-release capsules.
MAPLE GROVE, Minn., July 24, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Isotretinoin Capsules, USP in 10 mg, 20 mg, 30 mg, and 40 mg strengths. The Therapeutic Equivalence (TE) code for these Upsher-Smith products is AB1, and the original Reference Listed Drug (RLD) was the brand Accutane® (isotretinoin capsules USP).* This product launch is part of a multi-year, multi-product collaboration between Upsher-Smith and New Zealand-based, Douglas Pharmaceuticals Ltd. (Douglas). Douglas is a leading producer of isotretinoin around the globe.
MAPLE GROVE, Minn., June 26, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has entered into a definitive agreement under which New Jersey-based Tonix Pharmaceuticals Holding Corp. (Tonix Pharmaceuticals) and its wholly owned subsidiary Tonix Medicines, Inc. (Tonix Medicines) have acquired Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. As part of the transaction, Upsher-Smith will support the transition of the products by providing certain commercial operations, regulatory and other services to Tonix Medicines for up to nine months after closing. The closing is expected to take place on June 30, 2023. Stifel served as exclusive financial advisor to Upsher-Smith on this transaction and Ballard Spahr LLP represented the Company as legal counsel.
Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are Indicated for the Treatment of Acute Migraine in Adults Strategic Acquisition Helps Build Tonix™s Commercial...